Trial Profile
A Phase I Study Of Therapy With Mono-dgA-RFB4 In Patients With Relapsed And Refractory CD22+ B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody RFB4 ricin chain A conjugate (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 08 May 2014